Error loading player: No playable sources found

94821

Session II - Allogeneic Cell-based Therapies

Date
June 10, 2024
This product is not available for individual purchase, but it is available as part of the following products:

Allogeneic Cell-based Therapies


Allogeneic cell therapy products are long sought for expanding the success of cell based therapeutic approaches. Off the shelf products, manufacturable in relatively large quantities could significantly increase access for patients while reducing the cost of manufacturing for companies. The complexities of commercially manufacturing allogeneic cell products remain challenging.  Manufacturing changes are needed inevitable for the continuous process improvement.  Allogeneic cell therapy has the added challenge of the need to periodically replace the donor starting materials.  This is due to limitations in batch size based on the expansion of a single donor and hence requiring robust comparability evaluations. In this session, we will discuss the complexities of implementing a comparability strategy during manufacturing for allogeneic cell-based products. Presentations will be based on case studies in the clinical and commercial space involving healthy donor and induced pluripotent stem cells (iPSC) derived products. Panel discussions will center around phase appropriate strategies to implementing changes required to optimize manufacturing and donor replacement for allogeneic products. 



Session Speakers:



Analytical Control Strategy and Multi-Level Comparability for Genome Editing Components for Cell Therapy Products

Julien CamperiGenentech, a Member of the Roche Group


Regulatory Strategies & Comparability Assessment For Allogenic Cell Therapy Products With Variable Donor Starting Material 

Sangeetha PrakashTakeda Pharmaceutical Company Limited


Case Study in Comparability for an iPSC-Derived, Genome-Edited Cell Therapy Product

Jennifer DashnauCentury Therapeutics, Inc.


Related Products

Thumbnail for Plenary Session 8 - Global Regulatory Updates and Panel Discussion & Closing Remarks
Plenary Session 8 - Global Regulatory Updates and Panel Discussion & Closing Remarks
The cell and gene therapy field spans an enormous range of product types and technologies with the potential to provide curative treatments for a wide range of serious diseases…
Thumbnail for Session I - Autologous Cell-based Therapies
Session I - Autologous Cell-based Therapies
AUTOLOGOUS CELL-BASED MEDICINAL PRODUCTS
Thumbnail for CASSS Welcome & CGTP Summit 2024 Introduction
CASSS Welcome & CGTP Summit 2024 Introduction
ADVANCING COMPARABILITY UNDERSTANDING OF CELL-BASED MEDICINAL PRODUCTS